A pharmaceutical composition suitable for use in a dry powder inhaler comprising 70 mass% -99,5 mass% of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0,1 mass% -12,5 mass% of salmeterol xinafoate and 0,4 mass%-17,5 mass% of fluticasone propionate.